RC-148

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameRC-148
Drug Alias NameRC-148
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor inhibitorsProgrammed cell death protein 1 blockers
TargetsVascular endothelial growth factorProgrammed cell death protein 1
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesRemeGen Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAbbvie IncRemeGen Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A